

Natural flavonoids for the treatment of chronic obstructive pulmonary disease: An overview

Peng-Liang Shi^{1#}, Guo-Xuan Zhang¹, Pei-Yi Wang², Zi-Qi Liu¹, Bing-Qing Zheng^{1*}

¹School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.

²Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, China.

*Correspondence to: Bing-Qing Zheng, School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. E-mail: Zhengbq880223@126.com.

Author contributions

Shi PL collected documents and wrote the manuscript; Zhang GX, Wang PY, and Liu ZQ helped with information collection and manuscript editing; Zheng BQ revised the manuscript for important content and the manuscript preparation and editing.

Competing interests

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by the Shandong Provincial Traditional Chinese Medicine Science and Technology Project "Study on the mechanism of Astragalus polysaccharide inhibiting the occurrence of liver fibrosis through PD-1 regulating NK cell function (2020Q004)"; Shandong Provincial Medical and Health Science and Technology Development Project "Mechanism of STAT3 inhibition of liver fibrosis by regulating PD-1+NK cells (202002070991)". Natural Science Foundation of Shandong Province "Astragalus polysaccharides inhibit liver fibrosis by regulating CD49a+NK cells (ZR2022QH111)."

Abbreviations

COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; ROS, reactive oxygen species; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; NF- κ B, nuclear factor kappa-B; TNF- α , tumor necrosis factor-alpha; TGF- β , transforming growth factor- β ; IL-6, interleukin-6; IL-1 β , interleukin-1 beta; MMP9, matrix metalloproteinase 9; HDAC2, histone deacetylase-2; PI3K, phosphoinositide-3-kinase; Nrf2, nuclear factor erythroid 2-related factor 2; CXCL, C-X-C motif chemokine ligand; NE, neutrophil elastase; MAPK, mitogen-activated protein kinase; EGF, epidermal growth factor; LPS, lipopolysaccharide; TLR4, toll-like receptor 4; JNK, c-Jun N-terminal kinase; SOD, superoxide dismutase; GSH, glutathione; GSH-Px, glutathione peroxidase; HO-1, haem oxygenase 1; MDA, malondialdehyde; SIRT1, silent information regulator 1; NAD⁺, nicotinamide adenine dinucleotide; GPX4, glutathione peroxidase 4; NADPH, nicotinamide adenine dinucleotide phosphate; GR, glucocorticoid receptor; CSE, cigarette smoke extract; I κ B, inhibitor kappa B; HBECs, human bronchial epithelial cells; TLRs, toll-like receptors; IRAK, interleukin-1 receptor-associated kinase; PKC, protein kinase C; NOX4, NADPH oxidase 4; TIMP, tissue inhibitors of metalloproteinase; EMT, epithelial-mesenchymal transition; α -SMA, alpha smooth muscle actin; ERK, extracellular regulated protein kinases; AKT, protein kinase B.

Citation

Shi PL, Zhang GX, Wang PY, et al. Natural flavonoids for the treatment of chronic obstructive pulmonary disease: An overview. *Tradit Med Res*. 2025;10(9):57. doi:10.53388/TMR20241121001

Peer review information

Traditional Medicine Research thanks all anonymous reviewers for their contribution to the peer review of this paper

Editorial Advisory Board: lixiang

Executive editor: liuna.


Received: 22 November 2024; **Accepted:** 27 February 2025; **Available online:** 3 March 2025

© 2025 By Author(s). Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license. (<https://creativecommons.org/licenses/by/4.0/>)

Abstract

Chronic obstructive pulmonary disease (COPD) has been a major global public health issue due to its high prevalence, disability, and mortality rates. The pathogenesis of COPD is complex and remains incompletely understood, compounded by a lack of specific and effective clinical therapies. Key pathophysiological mechanisms include oxidative stress, inflammation, programmed cell death, and fibrosis, influenced by external risk factors such as cigarette smoke and internal factors like immune deficiency. Natural flavonoids emerge as promising adjuvant treatments or potential drug candidates for COPD, attributed to their multi-target properties and low toxicity. This article provides an overview of various types and sources of natural flavonoids that exhibit therapeutic effects on COPD, their specific pharmacological actions and detailed mechanisms of action. This review aims to serve as a reference for adjuvant treatment strategies in daily dietary practices and to inspire novel drug candidates for COPD.

Keywords: natural flavonoids; COPD; oxidative stress; inflammation; programmed cell death; fibrosis



Highlights

1. The effectiveness and diversity of traditional Chinese medicine in treating COPD promote the exploration of effective natural substances.

2. The structural diversity of natural flavonoids contributes to their ability to engage multiple pathways and mechanisms in the treatment of COPD.

3. The high safety and easy availability of natural flavonoids are significant advantages in both the prevention and treatment of COPD.

Medical history of objective

Extensive research on flavonoids in the treatment of COPD highlights the effectiveness of TCM for long-term management of lung diseases. For instance, the flower buds of *Tussilago farfara* L. were first documented in "Shennong's Classic of Materia Medica" (written during the Eastern Han Dynasty (25-220 C.E.)), which noted their ability to dissolve phlegm and relieve cough. Similarly, other ancient Chinese texts, such as "Newly Revised Materia Medica" (Jing Zhang et al. wrote in Tang Dynasty (659 C.E.)) and "Compendium of Materia Medica" (Shi-Zhen Li wrote in 1552-1578 C.E.), also recognized the same effects. Current pharmacological studies indicate that the flavonoids present in *Tussilago farfara* L. can combat COPD through various mechanisms, such as anti-inflammatory and anti-oxidative stress.

Introduction

Chronic obstructive pulmonary disease (COPD) is a progressive condition defined by persistent airflow obstruction and debilitating respiratory symptoms, presenting a considerable public health challenge across the globe. This illness leads to significant health issues and increased death rates, highlighting its effect on healthcare systems and individuals' quality of life. A report published by the World Health Organization indicated that COPD has escalated to the status of the third cause of death worldwide [1]. Furthermore, COPD will continue to increase in tandem with the aging global population [2].

The main pathological features of COPD include airway inflammation, airflow limitation, excessive mucus production, and damage to lung tissue. These factors result in symptoms such as wheezing, coughing, and shortness of breath, often leading to acute exacerbations or even death. The lungs are damaged by exposure to cigarette smoke (CS), dust, biofuel exhaust, and pathogens [3, 4]. COPD often overlaps with asthma and is often complicated by pulmonary hypertension and cardiovascular diseases, including systemic hypertension and atherosclerosis [5, 6]. Multiple theories have been used to elucidate the pathogenesis of COPD, including the regulation of local oxidative stress in the lungs, the degree of inflammation, the proteolytic homeostasis of the extracellular matrix (ECM), and the imbalance of autophagy and apoptosis [7-10]. Although the pathogenesis of COPD remains unclear, there is currently no specific treatment available. Palliative regimens focused on improving airflow limitation represent the primary clinical approaches. Thus, new strategies and drugs for blocking COPD development should be developed, and multiple pathological factors and targets should be considered.

Natural products are still a crucial source for drug screening and discovery because of their structural and functional diversity. Flavonoids are vital bioactive components found in natural plants, playing an essential role in maintaining health and alleviating diseases. Natural flavonoids are categorized based on their structural features and demonstrate various biological activities, including anti-inflammatory, antioxidative, cell-protective, antimicrobial, and ECM degradation [11, 12]. Furthermore, flavonoid intakes can not only alleviate COPD in experimental models but are also inversely associated with COPD incidence in smokers [13, 14]. Natural flavonoids, with the advantages of multi-target and low toxicity, have great potential in developing COPD drugs, but there are few reviews on the relevant content. The familiar sources of natural flavonoids and the mechanism of

action in treating COPD are shown in Figure 1. This article mainly summarises the pharmacological effects and specific mechanisms of natural flavonoids on COPD and provides a reference for the adjuvant treatment of COPD in daily dietary life and opinions for identifying new prospective candidate drugs for COPD.

Pathogenesis of COPD


COPD is a progressive respiratory condition defined by significant airflow limitation, mucus overproduction, chronic bronchitis, emphysema, or damage to the alveolar septal walls. These manifestations lead to symptoms such as wheezing, coughing, and dyspnea, which can result in acute exacerbations, hospitalisation, and even death [3].

CS, pathogens, and various environmental exposures are significant external risk factors contributing to the development of COPD; notably, the removal of these risk factors has the potential to halt the pathological progression of the disease [4, 15]. Other factors, including genetics, gender, occupation, airway hyperresponsiveness, lung growth and development, and infections, also significantly contribute to the pathogenesis of COPD [3-5]. COPD is characterised by persistent inflammation and fibrosis of the small airways and the deterioration of lung parenchyma, also known as emphysema [18, 19]. COPD is complicatedly regulated by various biological mechanisms and their crosstalk, including oxidative stress, inflammation, ECM homeostasis, apoptosis, pyroptosis, and mucous cell hyperplasia [7, 20-24]. Among these, the regulation mechanism of oxidative stress and inflammation has attracted much attention in the field of COPD research and drug discovery, and airway remodelling and fibrosis are critical pathological features of late-stage COPD.

Oxidative stress

Increased oxidative stress in the lungs significantly drives the disease through various molecular mechanisms [25, 26]. The anatomical structure of the lungs makes them highly vulnerable to damage from environmental oxidative stress. Reactive oxygen species (ROS) from mitochondrial respiration and responses to lung infections also play a regulatory role. In individuals diagnosed with COPD, there is a notable increase in both the quantity and activation of alveolar macrophages, leading to higher levels of ROS, such as superoxide anions and H₂O₂ [6]. The same outcome can also be triggered by an increase in neutrophils, particularly during exacerbations [7]. In addition, lung epithelial cells also produce oxidative stress due to mitochondrial respiration [8]. Excessive ROS production is induced by both exogenous stimulation and internal inflammatory conditions.

Increased oxidative stress can activate several signalling pathways to drive the pathophysiology of COPD. Oxidative stress releases a large amount of oxidants, leading to the inactivation of anti-proteases and disrupting the protease-antiprotease balance in lung homeostasis, particularly affecting α 1-antitrypsin [9]. The oxidative system is linked to the secretion of airway epithelial mucus, lead to the accumulation of ROS and induce high levels of mucus genes like mucin 5AC (*MUC5AC*) and mucin 5B (*MUC5B*) [10-12]. Epidermal growth factor receptor (EGFR) resided in oxidants-activated airway cells, which up-regulated the transcription of mucus genes during COPD development [34, 35]. Oxidative stress also triggers an inflammatory response in the lungs by influencing activator protein 1, an oxidant-sensitive transcription factor, and nuclear factor kappa-B (NF- κ B). These factors promote the expression of tumor necrosis factor-alpha (TNF- α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 β) [13]. In addition, oxidative stress activates transforming growth factor- β (TGF- β) signalling pathways, leading to small airway fibrosis and increased expression of matrix metalloproteinase 9 (MMP9) [14], which also enhances elastolysis by inactivating α 1-antitrypsin and secretory leukoprotease inhibitor, resulting in heightened neutrophil elastase activity and emphysema [15]. Moreover, corticosteroids play a significant role in suppressing pro-inflammatory gene expression [16]. However, oxidative stress can directly promote the phosphorylation and ubiquitination of histone deacetylase-2



(HDAC2) by activating phosphoinositide-3-kinase (PI3K)- δ [17], resulting in amplified inflammation and corticosteroid resistance [18].

Notably, nuclear factor erythroid 2-related factor 2 (Nrf2) will dissociate in oxidative stress response and transport to the nucleus to activate antioxidant gene transcription. Research indicates that the reduced self-protective mechanism in COPD patients is linked to decreased levels of Nrf2, leading to lower production of endogenous antioxidants. So, oxidative stress is a crucial mechanism of CS that initiates lung injury and inflammation and provides us with several targets, such as ROS and Nrf2, for drug discovery [19].

Inflammation and inflammatory cells

Inflammation drives the progression and exacerbations of COPD. In the airway lumen of COPD patients, inflammation is characteristic of increased numbers of macrophages, neutrophils, eosinophils, T cells, B cells, epithelial cells, endothelial cells, and fibroblasts [20]. The cells with different functions release different cytokines that work together to stimulate and maintain inflammatory levels and promote the progression and exacerbation of COPD.

CS stimulates both airway epithelial cells and macrophages to produce a range of chemotactic cytokines and chemokines, including IL-6, IL-8, C-X-C motif chemokine ligand (CXCL) 10, and CXCL9. These factors recruit neutrophils and CD8⁺ T cells to the airway [21]. CD8⁺ T cells are known to release perforins and granzymes, which contribute to tissue destruction and apoptosis. This process results in the production of pro-inflammatory proteases and cytokines, including IFN- γ and TNF- α , which may play a significant role in the pathogenesis of emphysema [22]. IFN- γ secreted by Th1, CD8⁺ cells, and B cells triggers a series of signalling cascades that induce macrophage polarized to M1 phenotype, which indeed produces pro-inflammatory cytokines. Such as, TNF- α promotes leukocyte accumulation by modulating endothelial adhesion molecules, which release elastase and ROS to destroy alveolar epithelium [46, 47]. Proteases such as MMP and neutrophil elastase (NE), released by neutrophils and macrophages, degrade connective tissue and elastin in the alveoli, leading to both localized (centrilobular) and generalized (panlobular) emphysema. MMP levels were significantly increased in COPD patients with emphysema, contributing to ECM degradation and initiating airway

tissue remodelling [23]. While CS-induced protease-antiprotease imbalance provokes airway inflammation for COPD pathogenesis, MMP and NE play crucial roles in the progression of emphysema and COPD [24]. Additionally, EGFRs can be activated by EGF released from neutrophils, or they may be indirectly activated through the mechanisms of oxidative stress [25]. Then, EGFRs activate mitogen-activated protein kinases (MAPK), which upregulate the expression of MUC5AC and MUC5B and lead to hyperplasia of goblet cells and submucosal glands, resulting in mucus hypersecretion and hyperplasia [26]. Moreover, macrophages and epithelial cells tend to secrete TGF- β to activate the fibrosis progress by proliferating epithelium, smooth muscle and fibroblasts. Thus, both the immune cells and airway epithelial cells are overly activated during the inflammation response and maintaining the stability of the pulmonary immune environment is a crucial problem in COPD treatment.

Fibrosis

Most types of chronic lung injury, primarily COPD, can induce fibrosis in the lungs, which occurs during the airway remodelling phase induced by persistent inflammatory stimulation and irreversible lung injury. Initially targeted at susceptible lung cells, recurring injuries caused by viruses, cigarette smoke, and others provoke epithelial cell death. Repairing the injuries increased vascular permeability, allowing fibrinogen and fibronectin to form a provisional matrix. Meanwhile, recurring injuries promote bronchiolar and alveolar epithelial cell migration and proliferation, including the aberrant-activated epithelial cells producing diverse epidermal growth factors (EGF) and chemokines to encourage the response. MMP1 and MMP7 are significant contributors to the migration of epithelial cells [27]. Following the migration of fibroblasts and fibrocytes to the sites of injury, these cells release MMP2 and MMP9, which activate TGF β 1. This activation subsequently facilitates epithelial-mesenchymal transition and promotes the differentiation of fibroblasts into myofibroblasts [28]. Myofibroblasts secrete ECM accumulation in the foci, mainly fibrillar collagens and alpha smooth muscle actin (α -SMA), and can provoke additional epithelial apoptosis through different signalling ways [52, 53].

In addition, lipopolysaccharide (LPS) and smoke stimulation can

also promote the occurrence of epithelial-mesenchymal transition (EMT) by up-regulating NF- κ B signalling, toll-like receptor 4 (TLR4)/c-Jun N-terminal kinase (JNK) signalling, and forkhead box O signalling [29]. Pulmonary fibrosis, a final stage of COPD, is a critical phase to prevent COPD from developing into a pulmonary malignant disease.

Flavonoids in COPD regulation

Traditional Chinese medicine possesses distinctive advantages in the treatment of COPD due to its inherent natural properties and demonstrated efficacy. Noteworthy, flavonoids, as the principal constituents of natural ingredients, offer outstanding anti-inflammatory and antioxidant properties, prompting significant interest and attention in scientific and industrial domains. Flavonoids can be categorized into 7 subgroups based on their structural variances, which include chalcones, flavones, flavonoid glycosides, Isoflavones, catechins (flavanols), biflavones and others. We have summarized 28 flavonoids that have been used in the treatment of COPD and divided them into 6 categories, which can be visualized in Figure 2.

The different biological activities of flavonoids depend on the three rings C6-C3-C6 essential backbone and different substitution groups. In addition, we have made a detailed summary of the natural sources of flavonoids in order to provide a reference for the public's daily diet. The leading information can be seen in [30–97].

□□□□□□

The use of natural compounds and traditional Chinese medicine for managing COPD has been increasingly recognised. Patients with COPD should consider integrating these treatments into their overall care plan. Specifically, flavonoids have the potential to regulate imbalances in protease-antiprotease activity, immune function, lung function changes, blood flow, and serum markers by addressing airway and lung inflammation, improving airway remodelling, reducing airway reactivity, and modulating oxidative-antioxidant processes. Below, we summarise the potential efficacy of flavonoids in the treatment of COPD by discussing the specific mechanisms of action of these compounds. The detailed experimental verification can be found in [30–97].

□□□□□□

Flavonoids targeting oxidative stress

Targeting ROS and antioxidative enzymes. Oxidative stress accelerates the pathogenesis of COPD [98]. Harmful substances such as CS can cause inflammatory cells such as neutrophils and macrophages to accumulate in the lungs, producing large amounts of ROS [99]. In turn, ROS stimulates the expression of various inflammatory mediators in the lungs and results in hyper-mucus secretion by airway epithelial cells [125, 126], aggravating the development of COPD.

Flavonoids have been reported to prevent and inhibit lung injury by scavenging free radicals. Flavonoids enhance intrinsic antioxidant capacity by increasing the levels and activities of antioxidant enzymes such as catalase, superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px), while also inhibiting ROS-generating enzymes like xanthine oxidase. For example, puerarin reversed mitochondrial membrane potential levels and ATP levels and decreased ROS content in cigarette smoke extract (CSE)-stimulated human bronchial epithelial cells (HBECS) [81]. Baicalin exerted an antioxidant role in CS-induced COPD mice by enhancing SOD, haem oxygenase 1 (HO-1) and reducing malondialdehyde (MDA) levels [65]. Liquiritin inhibited oxidant stress by increasing the SOD levels of the lung in CS-induced ICR mice [76]. Biochanin A increased the levels of antioxidant enzymes such as GSH-Px and decreased MDA, lactate dehydrogenase and alkaline phosphatase in a rat model of PM_{2.5} exposure [80]. Apigenin enhanced the activation of silent information regulator 1 (SIRT1), nicotinamide adenine dinucleotide (NAD⁺), and the NAD⁺/NADH ratio in H₂O₂-induced WI-38 cells [36]. By regulating the balance between the antioxidant and ROS-generating enzymes, the flavonoids above can alleviate lung tissue lesions in COPD.

Targeting Nrf2/HO-1. Nrf2 serves as a pivotal transcription factor that governs the expression of genes associated with antioxidant activity. In patients with COPD, low levels of Nrf2 can diminish the body's antioxidant capacity [100]. Under normal conditions, Kelch-like ECH-associated protein 1 sequesters Nrf2 in the cytoplasm. However, under oxidative stress, Nrf2 is released and translocated to the nucleus, where it initiates the transcription of various antioxidant genes, including glutathione (GSH), glutathione peroxidase 4 (GPX4), nicotinamide adenine dinucleotide phosphate (NADPH), NADPH quinone dehydrogenase 1, HO-1, 6-phosphogluconate dehydrogenase, thioredoxin, and the glucocorticoid receptor (GR) [128, 129].

Various flavonoid monomers have been shown to have protective effects on airway epithelial cells and inflammatory cells. In summary, flavonoids were found to inhibit oxidative stress and inflammatory responses by targeting Nrf2 in different cell types, including epithelial cells, macrophages, and lung cancer cells. The mechanism of action can be visually illustrated in Figure 3. Casticin enhanced SOD activity but decreased ROS and MDA by regulating Keap1-Nrf2/antioxidant response element signalling way in H₂O₂-induced BEAS-2B cells [53]. Oroxylin A reduced the inflammatory response by increasing Nrf2 levels in CS-damaged RAW 264.7 cells [37]. Luteolin decreased total ROS and mitochondrial ROS concentrations by inhibiting CYP2A13 expression while simultaneously increasing Nrf2 levels in CSE-treated A549 cells [55].

In mice and rat models of COPD, various flavonoids have likewise been proved to inhibit the development of COPD by modulating Nrf2-related oxidative stress to attenuate lung damage and inflammatory responses. In a four-days CS-induced mouse model, Oroxylin A increased GSH, GR, GPx-2 and HO-1 levels by promoting Nrf2 binding to antioxidant response element [37]. In a CS-induced mouse model, isoliquiritigenin reduced MDA levels by enhancing the expression of Nrf2 and HO-1 [32]. Fisetin was demonstrated to prevent lung damage and attenuate oxidative stress and inflammation via Nrf2-mediated antioxidant factors in CS-induced rat model, including decreasing inflammatory cytokines such as IL-4, IL-1 β , TNF- α and increasing antioxidant enzymes such as SOD, GSH [48]. Epicatechin repressed the production of ROS by enhancing the Nrf2-induced anti-oxidant enzyme and then reduced IL-18 and IL-1 β levels by inhibiting the NLRP3-Caspase-1 pathway in the CS-induced rat [84]. Luteolin inhibited oxidative stress by decreasing the TRPV1 and CYP2A13 proteins while increasing SIRT6 and Nrf2 levels in CSE-treated A549 cells and CS- and LPS-induced COPD mice [55]. Additionally, flavonoids could target Nrf2 and reverse dexamethasone tolerance during COPD treatment. Quercetin was reported to reverse the dexamethasone-tolerance in CSE-induced U937 cells by activating adenosine 5'-monophosphate-activated protein kinase (AMPK) and Nrf2 signalling way [40].


Total flavonoids of natural plants have also been reported to inhibit oxidative stress in COPD by targeting Nrf2. Dandelion total flavonoids improved lung function and reduced oxidative stress-induced lung damage by upregulating antioxidant enzymes such as SOD and GSH in mice exposed to CS, linked to the activation of the Nrf2 signaling pathway [97].

Flavonoids targeting inflammation


Inflammation is a vital component in the initiation and advancement of COPD. The infiltration of neutrophils demonstrates a positive correlation with the severity of airflow obstruction. Harmful substances induce the respiratory tract epithelium to secrete inflammatory cytokines and chemokines. Likely, TNF- α facilitates leukocyte migration and accumulation by stimulating pulmonary endothelial cells, releasing lysosomal enzymes, elastase, and ROS, all detrimental to endothelial cells and the alveolar epithelium [101]. IL-6 activates neutrophils, releasing NE and ROS, which damage alveolar surfactants, increase pulmonary vascular permeability, and induce pulmonary edema [102]. Additionally, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 α serve as chemoattractants, recruiting inflammatory cells such as macrophages and lymphocytes into inflamed tissues.

Chalcones


Phloretin




Isoliquiritigenin




Hydroxysafflor yellow A

**Flavones**


Apigenin




Oroxylin A




Scutellarein




Quercetin




Fisetin




Myricetin




Casticin




Luteolin




Naringenin




Hesperetin

**Flavonoid glycosides**


Baicalin




Astragalin




Icarin




Liquiritin apioside




Tilianin

**Isoflavones**


Formononetin




Biochanin A




Puerarin

**Catechins**


Epicatechin




Epigallocatechin Gallate

**Other flavonoids**


Silibinin




Silymarin



ginkgetin





Flavonoids possess strong anti-inflammatory properties in various inflammatory diseases, effectively inhibiting the onset and progression of COPD. Additionally, flavonoids play a significant role in addressing respiratory diseases closely linked to inflammation. We will focus on the anti-COPD effect of flavonoids and their related mechanisms of action, including their relationship with NF- κ B signalling pathway, MAPK signalling pathway, EGFR signalling pathway, and immune cells migration. The different mechanisms of action that flavonoids protect COPD can be seen intuitively in Figure 4.

Targeting NF- κ B pathway. The activation of the NF- κ B pathway is believed to play a pivotal role in inflammatory diseases, including airway and pulmonary inflammation. Under normal conditions, NF- κ B remains inactive in the cytosol, as it is bound to the inhibitor kappa B (I κ B). Upon stimulation of airway epithelial receptors, I κ B kinase is activated, leading to the phosphorylation of I κ B α or I κ B β . This phosphorylation results in the dissociation of I κ B α or I κ B β from NF- κ B. Subsequently, NF- κ B (comprising p50 and p65 subunits) translocates to the nucleus, where it activates the expression of genes encoding inflammatory cytokines and chemokines, such as *TNF- α* , *IL-1 β* , and *IL-6* [103]. Notably, activated NF- κ B in the lung tissue of COPD patients were significantly elevated, while I κ B levels were notably reduced [104]. Furthermore, the inhibition of the NF- κ B pathway led to a decrease in the presence of respiratory mucus, specifically MUC5AC and MUC5B [105].


Researchers have identified a range of natural products that modulate NF- κ B signalling in COPD, acknowledging NF- κ B's significance in chronic inflammatory conditions. Casticin was reported to inhibit the apoptosis and pro-inflammatory cytokines (TNF- α , IL-6, IL-1 β , and IFN- γ) production by down-regulating p-p65 but increasing Nrf2 in LPS-induced BEAS-2B cell [52]. Epigallocatechin gallate diminished the lipid peroxidation, ROS production and inflammation mediator levels (COX-2, NADPH oxidase 4 (NOX4), NOS2, IL-6 and IL-8) by suppressing the activation of NF- κ B pathway in CSE-stimulated airway epithelial

cells [85]. Baicalin inhibited the TNF- α , IL-8, and MUC5AC levels by decreasing NF- κ B p65 phosphorylation in IL-1 β -induced NCI-H292 cells [69], in CSE-induced type II pneumocytes and in CS-exposed rat [63]. In a CS-induced mouse model, Isoliquiritigenin reduced the phosphorylation of p65 and I κ B, attenuating the inflammatory response and reducing the inflammatory factors [32]. Casticin improved lung function and reduced the number of white blood cells, neutrophils, and macrophages and the level of leptin, C-reactive protein, and pro-inflammatory cytokines by inhibiting the NF- κ B and iNOS pathway [51]. Taxifolin significantly suppressed elevated IL-1 β , IL-6 and TNF- α levels in COPD mouse lung tissue and CSE-treated HBECs by inhibiting the phosphorylation p65 NF- κ B [62].

In addition, glucocorticoid drugs are often used to improve airflow limitation and attenuate the inflammation of COPD in clinical, which usually induces drug tolerance at the same time. Several kinds of flavonoids decreased the inflammation levels and reversed the glucocorticoid drug tolerance at the same time. In CS exposure mice and pig models, naringenin not only significantly improved the pulmonary function but decreased the accumulation of inflammatory cells and pro-inflammatory cytokines such as IL-8, TNF- α , and MMP9 by inhibiting phosphorylation of NF- κ B but increasing GR, which indicate that naringenin enhances the corticosteroid sensibility [48, 82]. Icariin demonstrated a significant reduction in inflammation, airway remodelling, and ROS production that is induced by CSE. Furthermore, it alleviated glucocorticoid resistance through the down-regulation of the Nrf2 and NF- κ B signalling pathways [73].

Flavonoids can directly act on the NF- κ B pathway to improve COPD inflammation. However, as a core pathway, its upstream regulators, including toll-like receptors (TLRs) and sirtuins, also regulate its activation.

TLRs are a family of receptors that detect pathogens and tissue damage. Among them, TLR2 recognizes lipoteichoic acid from gram-positive bacteria, and TLR4 is activated by LPS and other endogenous ligands [106], which were reported to be up-regulated



and activated during COPD initiation and development, especially in the COPD co-infection model. Upon stimulation, myeloid differentiation primary response gene 88 recruits the interleukin-1 receptor-associated kinase (IRAK) family member IRAK4 to TLRs and induces the phosphorylation of IRAK1, which subsequently activates the NF-κB pathway [107]. In CS and LPS co-induced COPD rat model, baicalin reduced TLR2 and TLR4, followed by lowering MYD88, phosphorylation of p65, and increasing phosphorylation of IκBa [70], Total flavonoids of *Trollius altaicus* downregulated TLR4 to reduce the activation of IRAK-1, thereby reducing the activation of the NF-κB and reducing IL-1β, IL-6, IL-8, TNF-α [95]. In long-term CS-exposed rats, casticin reduced TLR4 expression to inhibit the NF-κB phosphorylation and increase the IκBa phosphorylation level, thereby reducing inflammation [51]. TLRs are crucial targets of flavonoids in inhibiting COPD-associated inflammation, especially in infection-associated COPD development.

SIRT1, one of seven-number families with different subcellular localisations and functions, is the first sirtuin that regulates inflammatory, oxidative stress, autophagy, and apoptosis, which can inhibit the activation of NF-κB. The heightened inflammatory response may reduce SIRT1 levels in patients with COPD [108], and a high level of SIRT1 inhibits inflammatory reactions in lung cells stimulated by CS [109]. Quercetin increased SIRT1 levels to reduce inflammatory responses and oxidative stress in mice with COPD induced by LPS and elastase [39]. Myricetin reduced IL-6 and IL-8 levels in TNF-α-induced A549 cells by regulating the SIRT1/NF-κB pathway [49]. Hesperetin alleviated inflammation and oxidative stress responses by SIRT1/PGC-1a/NF-κB signalling axis in CES-induced COPD mice [59]. Besides, total flavonoids of *Scutellaria baicalensis* Georgi also inhibited inflammatory and oxidative stress by increasing SIRT1 and PGC-1a levels in CS- and LPS- co-induced mice models [93].

There are also several other targets for flavonoids to regulate NF-κB during COPD inflammation, such as protein kinase C (PKC)δ, peroxisome proliferator-activated receptor γ, HDAC2 and NOX4.

Fisetin has been reported to directly bind to PKCδ, preventing the activation of NF-κB and the expression of IL-8 in HEK293T and NCI-H292 cells induced by TNF-α [47]. Icarin promoted lung function and reduced TNF-α and IL-6 levels in bronchoalveolar lavage fluid and serum of COPD rat model, and indeed up-regulated the peroxisome proliferator-activated receptor γ expression and inhibited the activation of p65 of lung and epithelial cells [75]. Baicalin treatment markedly attenuated the inflammatory effects through down-regulating airway inflammatory infiltration and decreasing the inflammatory factors (the levels of TNF-α and IL-1β) in CS/CSE-exposed rats and cells, which attributed to the enhancement of HDAC2 protein expression and inhibition of NF-κB or even targeting its downstream effector PAI-1 [89, 92]. Luteolin reduces inflammation and oxidative stress via the NOX4-mediated NF-κB pathway in CS-induced cell and mice [54].

Total flavonoid extract also has the effect of inhibiting the NF-κB pathway. For example, total flavonoids from *Nigella glandulifera* relieved the pathological state, inhibited the infiltration of neutrophils and macrophages into the lung and decreased levels of TNF-α and IL-8 via the NF-κB pathway [91]. Total flavonoids from loquat (*Eriobotrya japonica*) leaves alleviated oxidative stress-induced lung injury, emphysema and inflammation by inhibiting NF-κB and JNK phosphorylation [94].

Targeting MAPK pathway. MAPKs represent a diverse family of kinases that are critical components of various signal transduction pathways. The MAPK family comprises four subfamilies: extracellular regulated protein kinases (ERK)1/2 (extracellular signal-regulated kinases 1 and 2), ERK5, JNKs, and p38s (p38 MAPKs). Notably, p38 MAPK is activated in response to environmental stress and inflammatory stimuli. Of its subtypes, p38α is particularly abundant in inflammatory cells [110]. Moreover, elevated levels of p38 MAPK have been detected in the airways and sputum of COPD patients [111]. Furthermore, it has been demonstrated that pathogens can augment MUC5AC mucin secretion by activating the p38 MAPK pathway while simultaneously inhibiting the PI3K-Akt pathway [112].

In mice exposed to CS, astragalus demonstrated an ability to attenuate inflammation and oxidative stress induced by pulmonary thrombus. This effect was mediated by a reduction of PAR-1 and PAR-2, which subsequently inhibited the production of ROS and the expression of COX-2, iNOS, and ICAM-1. The mechanism involved the inhibition of the ERK, p38, and JNK signalling pathways [72]. Silymarin significantly alleviated the thickening of the airway epithelium and infiltration of peribronchial inflammatory cells (including total cells, macrophages, and neutrophils) while also reducing levels of pro-inflammatory factors such as TNF- α , IL-1 β , and IL-8 by attenuating the phosphorylation of ERK and p38 in CS-exposed mice, the results were also proved in CSE-induced Beas-2B cells [113, 114]. The total flavonoids of *Trollius altaicus* protected lung function by inhibiting the activation of p38 and ERK in CS-induced mice [96].

Bacterial infection stands as a primary culprit behind acute exacerbations of COPD. These exacerbations correlate with a notable rise in both airway and systemic inflammation [113]. Flavonoids alleviate the pathological inflammation associated with COPD combined with bacterial infection by inhibiting the activation of MAPKs. Applying LPS/CSE-induced acute exacerbations of COPD mouse models, researchers discovered that: Hydroxysafflor yellow A decreased levels of IL-6, IL-1 β , and TNF- α by inhibiting the phosphorylation of ERK, p38, and JNK, and to inhibit inflammatory mediator by decreasing levels of p-p38 and p-p65, as well as in platelet-activating factor (PAF)-stimulated HSAECs [59, 60]; Baicalin reversed elevated levels of IL-8, IL-6, TNF- α and MUC5AC which is associated with the inhibition of JNK activation [66]; Silibinin inhibited the expression of MUC5AC, IL-6, and IL-1 β by suppressing the activation of ERK and specificity protein 1, as well as in CS condensate-stimulated NCI-H292 cells [86]. Total flavonoids of sea buckthorn inhibited expression of IL-1 β , IL-6, CXCL1, prostaglandin E2, cyclooxygenase-2, and MUC5AC through the inhibition of the ERK, PI3K/Akt, and PKC α pathways, as well as in LPS/CSE-induced HBE16 cells [92].

Targeting EGFR pathway. The EGF and its receptor (EGFR) are essential for causing and promoting various cell growth, proliferation, and transformation processes. Patients with COPD have higher levels of EGFR in their lungs compared to smokers without COPD symptoms [114]. This suggests that EGFR plays a significant role in the development of COPD. The increased EGFR levels are linked to the growth of airway epithelial goblet cells and more mucus production [25]. EGFR activation initiates key signaling pathways, including PI3K/protein kinase B (AKT)/mTOR, RAS/MEK/ERK, and MAPK p38 [115].

Flavonoids inhibit the activation of the EGFR signalling pathway, making them promising for treating lung diseases. In CS-exposed mice and CSE-induced NCI-H292 cells, phloretin decreased EGFR phosphorylation, reducing ERK phosphorylation and p38 expression and decreasing mucin expression and inflammation [30]. In the LPS-induced airway mucus hypersecretion rat model, quercetin reduced the expression level of MUC5AC by inhibiting the activation of the EGFR, as evidenced by decreased levels of p-EGFR/EGFR, p-PI3K/PI3K, p-PKC/PKC, p-AKT/AKT, and NF- κ B [44]. Additionally, in EGF-stimulated H292 cells or A549 cells, tilianin also reduced MUC5AC expression by modulating the expression of AKT, ERK, and p38 in EGF-stimulated NCI-H292 human airway epithelial cells. However, it did not affect A549 cells [77]. Furthermore, icariin was shown to promote lung function and reduce pro-inflammatory cytokines by inhibiting the phosphorylation of PI3K, AKT, and p38 [74].

Immune cells migration. The inflammatory process of COPD is characterized by the persistent migration of inflammatory cells from the blood vessels to the lungs. This includes neutrophils, macrophages, and T cells, which produce a plethora of cytokines that exacerbate inflammation.

Casticin was found to inhibit immune cell infiltration in the lungs, including neutrophils, macrophages, and lymphocytes. This effect was accompanied by a downregulation of TNF- α , IL-6, IL-1 β , and monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of CS-exposed mice [50]. Phloretin was shown to reduce the level of CXCL1, a neutrophil chemoattractant, which was induced by nontypeable *Haemophilus influenzae* in a COPD

model of infection [31]. Quercetin improved the lung function and alleviated goblet cells metaplasia and emphysematous by down-regulating the inflammation mediators levels (such as CXCL-1, CXCL-10, TNF- α , IFN- γ IL-13 and IL-17A) and infiltration of immune cells (such as leukocytes, total lymphocytes, CD11b⁺CD11c⁺ macrophages, neutrophils and CD8⁺T cells) in both CS-induced and rhinovirus/CS-induced COPD mice [66, 70]. Quercetin also improved epithelial regeneration and reduced TGF- β , IL-6 and IL-8 airway basal cells of COPD patients [46]. Tilianin inhibited neutrophil infiltration in the lung by affecting CXCL2, IL-17/STAT3 signal pathways in the COPD mice model [78]. Ginkgetin decreased CCL2 levels by downregulating the c/EBP β signalling pathway in CSE-induced A549 cells, which is associated with immune cell migration such as macrophages [90]. Additionally, naringenin inhibited the M1 polarization of macrophages induced by extracellular vesicles from CSE-induced epithelial cells and reduced inflammatory cells and myeloperoxidase in CS-exposed guinea pigs [81, 83]. Additionally, naringin has a protective effect on NEP activity by reducing SP and the expression of the NK-1 receptor, thereby relieving the cough symptoms in CS-exposed guinea pigs [79].

Flavonoids targeting airway remodelling and fibrosis


There is currently insufficient data on how flavonoids affect the anti-COPD fibrosis process. These studies primarily focus on the formation and degradation of ECM and the process by which fibrotic cells are formed. Figure 5 offers more detailed insights into the specific mechanisms of action involved.

ECM degradation. Proteases are key in remodelling tissue and promoting inflammation [23]. An imbalance between proteases and anti-proteases disrupts ECM, which is essential for maintaining the dynamic integrity of organs. MMPs, serine proteases, and caspases are the three main elastase types responsible for hydrolysis peptides and other proteins. MMP-2, MMP-8, MMP-9, and NE are most involved in emphysema and COPD [49, 145-147]. Among them, MMPs are a prominent and influential family. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs; usually, TIMP-1 inhibits active MMPs, and TIMP-1 binds to pro-MMP-9 to prevent the activation of pro-MMP-9. However, under harmful conditions, the combination of TIMP-1 and pro-MMP-9 dissociates by NE action, and MMP-3 activates pro-MMP-9 to MMP-9 [116]. NE, cathepsin G, and proteinase-3 are three main types of serine proteases that are also destroyed by degrading ECM components of lung tissue [117]. ECM degradation releases collagen and elastin, which attract immune cells and cause ongoing airway inflammation in the lungs.

In CS-exposed mice, quercetin [39], naringenin [57], hesperidin [60], and baicalin all downregulated MMP9 levels and reduced inflammation [65]. Baicalin also reduced TIMP-1, MMP2, MMP9, and MMP8 [64]. In CSE-induced BEAS-2B cells, icariin reduced the expression of MMP-9 and TIMP1 [73]. Thus, flavonoids inhibited ECM degradation and maintained alveolar integrity in the early phase of COPD development.

Fibrosis. In patients with COPD, airway epithelial cells show higher levels of TGF- β 1 expression, which contributes to fibrotic airway remodelling and a decline in lung function [118]. TGF- β activates TGFBR, promoting the phosphorylation of Smad2/3. The phosphorylated Smad2/3 subsequently binds to Smad4, initiating the transcription of genes related to airway remodellings, such as α -SMA and collagen. This process alters the EMT [119]. Additionally, TGF- β signalling upregulates MMPs, facilitating EMT and resulting in the degradation and destruction of lung tissue. Furthermore, TGF- β induces the EGF/EGFR signalling pathway, which synergistically promotes EMT-related phenotypic changes. TGF- β 1 also stimulates the activity of neutrophils, macrophages, and mast cells.

Hydroxysafflor yellow A reduced the expression of TGF- β 1 in a rat model of LPS-CS co-infection and alleviated pulmonary fibrosis by decreasing the accumulation of α -SMA and collagen I, thereby improving lung function [33]. In four-day CS-exposure mice, liquiritin apioside reduced inflammatory response and TGF- β 1 level. The same results were performed in CSE-induced A549 [76]. In a three-month CS-exposed mouse model, quercetin also reduced



TGF- β 1 and α -SMA in the lungs [42]. In the CS-exposed mouse model, silibinin decreased collagen accumulation by modulating the TGF- β 1/p-Smad 2/3 signalling axis and simultaneously attenuated the expression of inflammatory factors [87]. Besides, in the LPS-CS co-induced rat model, total flavonoids of *Trollius altaicus* were shown to decrease TGF- β 1 levels [95]. Both short-term and long-term exposure to smoke can result in lung inflammation and cellular damage, leading to the production of TGF- β 1, implicating the initiation of pulmonary fibrosis. However, flavonoids, such as hydroxysafflor yellow A, liquiritin apioside, quercetin, silibinin, and total flavonoids of *Trollius altaicus* may help prevent the progression of COPD to pulmonary fibrosis by reducing TGF- β . Compared with the anti-inflammatory and antioxidant studies of flavonoids, there are few studies on anti-pulmonary fibrosis, and most of them only reduce TGF- β , which suggests that more extensive and in-depth research is needed.

Flavonoids targeting programmed cell death

Targeting apoptosis. Apoptosis is a physiological or pathological response of cells to various stimuli, including DNA damage, oxidative stress, and inflammation. This process is complex and tightly regulated by multiple genes, such as the *Bcl-2* family, the caspase family, the oncogene *C-myc*, and the tumour suppressor gene *P53*, as well as by various molecular signals, including the death receptor pathway and the mitochondrial pathway [120]. Research shows that the apoptosis (cell death) of lung structural cells is a crucial factor in the development of COPD. In patients with COPD, there is an observed increase in the apoptosis of alveolar epithelial and endothelial cells. This increase cannot be compensated for by the proliferation of structural cells, leading to the destruction of lung tissue and the development of emphysema [121].

Flavonoids have been reported to act as positive protectors against apoptosis in the pathogenesis of COPD. For instance, baicalin has been shown to inhibit the expression of HSP72 and alleviate apoptosis in CSE-treated MLE-12 cells, which are mouse lung type II epithelial cells [66]. Additionally, baicalin mitigates the apoptosis of LPS- or CSE-induced 16HBE cells by increasing Bcl-2 and CyclinD1 but increasing B-cell lymphoma 2-associated X (Bax) and P21 [92, 93, 96]. Taxifolin inhibited apoptosis by suppressing Bax and CCP3 levels and increasing Bcl-2 levels in COPD mouse lung tissue and CSE-treated HBECs [62]. Hesperetin

is capable of suppressing the protein expression of AKT1, IL6, VEGFA, and MMP9 while up-regulating the protein expression of TP53, thereby impeding COPD to lung cancer [60]. Furthermore, flavonoids regulate autophagy-related apoptosis. Puerarin has been demonstrated to inhibit FUNDC1-mediated mitochondrial autophagy and CSE-induced apoptosis in human bronchial epithelial cells by activating the PI3K/AKT/mTOR signalling pathway [81]. Puerarin also protects lung function and inhibits apoptosis by down-regulating the Bax level and up-regulating Bcl-2 in the lung, a process that depends on the PINK1-parkin signalling pathway mediated mitophagy [82]. Moreover, formononetin can attenuate CS-induced inflammation, endoplasmic reticulum stress, and apoptosis in bronchial epithelial cells through the inhibition of AhR/CYP1A1 and AKT/mTOR signalling pathways [83]. In addition, flavonoids inhibit apoptosis associated with inflammation. Biochanin A has been shown to reduce PM2.5-induced apoptosis and the production of pro-inflammatory factors, such as TNF- α , IL-2, IL-6, and IL-8 [80].

Targeting ferroptosis. Ferroptosis, a form of regulated cell death, is driven by an excessive accumulation of iron, ROS, and lipid peroxides. This process leads to a decrease in GSH and the inactivation of GPX4 [122]. Ferroptosis is increasingly recognised as a critical factor in COPD, with levels elevated in free iron, lipid peroxidation, and inflammatory responses in mice, which are reversed by the overexpression of the GPX4 [123]. GPX4, a negative regulator of ferroptosis, was significantly downregulated in HBECs, which correlates with exacerbations of airway obstruction. Additionally, acyl-CoA synthetase long-chain family member 4 (ACSL4) has been identified as a significant contributor to sensitivity to ferroptosis and was significantly upregulated [124]. Furthermore, Nrf2 plays a protective role by inhibiting ferroptosis through the scavenging of ROS and the promotion of GSH synthesis [125].

Scutellarein may help treat COPD by inhibiting ferroptosis through iron chelation and interaction with the enzyme arachidonate 15-lipoxygenase, which is involved in fatty acid oxidation. Besides, scutellarein significantly inhibited Ras-selective lethal small molecule 3-induced ferroptosis and mitochondria injury [38]. Dihydroquercetin significantly inhibited the ferroptosis induced by CS through the Nrf2-dependent signalling pathway. It notably impeded the increasing of lipid peroxidation and morphological changes in the mitochondria by up-regulating SLC7A11, GPx4, and SOD by down-regulating MDA and ROS [61]. Naringenin increased the extracellular vesicles miR-23a-3p

level of CSE-induced alveolar macrophages and inhibited lung epithelial ferroptosis by targeting ACSL4 [58]. Thus, flavonoids could alleviate the ferroptosis-induced injury and oxidative stress by chelating iron and activating the downstream anti-oxidant pathway during the progression of COPD.

Flavonoids' safety

Flavonoids have a long history of consumption in diets with high-rich flavonoids, and a high intake of flavonoids has not caused any side effects. As a result, it is unlikely that dietary sources could provide doses sufficient to cause mutations or cytotoxicity. However, pharmacological and clinical experiments have shown that a variety of flavonoid preparations have certain toxicity, consult Table 3 [68, 158-171] for additional details. For example, chalcones, such as isoliquiritigenin has mortality and malformation [126], hydroxysafflor yellow A has a slight nephrotoxicity in long term [127]; Flavone glycosides certain, baicalin has certain renal toxicity [128]. Isoflavones, such as puerarin has the severity of adverse drug reactions depends on the choice of infusion solvent [129], not the dosage of puerarin, formononetin has mortality at acute dose 300 mg/kg and LD50 at 103.6 mg/kg [130]. Bisflavonoid, such as ginkgetin has potential hepatic and renal toxicity [131]. There are tens of thousands of types of flavonoids, and the safety of each flavonoid compound is extensive, so it is of great significance to investigate the side effects of daily flavonoid supplementation.

□□□□□□

Conclusion and prospect

Natural flavonoids are a class of compounds commonly found in various foods, and herbs derives its properties from a wide range of plants, including apples, celery, bayberry, citrus, tea, and ginkgo, as well as astragalus and licorice. A significant body of research exists regarding the flavonoid content in different food sources. Among the flavonols and flavones, quercetin is the most prevalent compound which is particularly abundant in onions and tea. Other noteworthy flavonoids include kaempferol, myricetin, as well as the flavones apigenin and luteolin.

COPD is a prevalent and fatal chronic lung disease that poses a significant burden on global healthcare systems. Despite its high incidence, the mechanisms underlying the development of COPD remain elusive, and there are currently no drugs available to prevent or reverse its initiation and progression. As discussed in this review, flavonoids can target multiple pathways to inhibit the development of COPD, including regulating oxidative stress by targeting ROS and Nrf2/HO-1, reduce inflammation by targeting NF- κ B, MAPK, and EGFR pathway, remodel airway by reducing ECM and fibrosis, and regulate programmed cell death by targeting apoptosis and ferroptosis. All of this indicates that flavonoids offer unique advantages in drug discovery and adjuvant therapy but also suggests that foods rich in flavonoids can be used to prevent the occurrence of COPD.

The structure of flavonoids is both complex and diverse. As discussed in this review, the structures of flavonoids exhibiting therapeutic effects on COPD vary significantly. Notably, the number and position of hydroxyl groups influence flavonoids' activity and mechanism of action, with the ortho-hydroxyl group playing a particularly critical role. Additionally, glycosylation represents another important structural feature that impacts efficacy. However, research related to COPD has not thoroughly and specifically addressed the structure-activity relationships of flavonoids. Elucidating these relationships, along with conducting structural modifications and optimisations, is essential for guiding the development of anti-COPD drugs.

A variety of flavonoids have been developed into pharmaceuticals, cosmetics, and health foods, such as ginkgo flavonoids, tea polyphenols, and puerarin. Flavonoids as dietary supplements are not regulated as strictly as drugs, do not need to be reviewed by the FDA, and are not thoroughly evaluated for potential toxicity. When people use these drugs, cosmetics, or health foods, the recommended intake of flavonoids is much higher than in the daily diet, usually at the gram level. Therefore, people need to

pay attention to the dosage when supplementing with additional flavonoid preparations to avoid adverse reactions.

Many flavonoid compounds, as well as flavonoid-rich diets and medications, are utilized in clinical treatments, demonstrating their relative safety for human health, only quercetin has explicitly been tested in clinical trials for treating COPD [43]. Consequently, which flavonoid is most suitable for COPD therapy remains unclear, underscoring the need for further preclinical and clinical research. Currently, there have been only two clinical trials involving quercetin and a flavonoid-rich diet for COPD [13, 14]. Nonetheless, numerous other clinical trials have established the safety of flavonoids, which can serve as a reference for conducting trials related to COPD. In addition, the combination of flavonoid compounds with other drugs is also an important strategy.

This article provides a comprehensive overview of flavonoids employed in the treatment of COPD. It delineates their primary sources, structural classifications, and the various mechanisms of action and therapeutic targets. This information serves as a crucial reference for the dietary management and treatment strategies for patients suffering from COPD. Furthermore, it offers valuable insights for researchers concerning structural attributes, pharmacological effects, and potential toxicities. Additionally, the article establishes a foundation for future clinical trials aimed at advancing the treatment methodologies for COPD.

Author contributions

Shi PL collected documents and wrote the manuscript; Zhang GX, Wang PY, and Liu ZQ helped with information collection and manuscript editing; Zheng BQ revised the manuscript for important content and the manuscript preparation and editing.

Competing interests

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by the Shandong Provincial Traditional Chinese Medicine Science and Technology Project "Study on the mechanism of Astragalus polysaccharide inhibiting the occurrence of liver fibrosis through PD-1 regulating NK cell function (2020Q004)"; Shandong Provincial Medical and Health Science and Technology Development Project "Mechanism of STAT3 inhibition of liver fibrosis by regulating PD-1⁺NK cells (202002070991)". Natural Science Foundation of Shandong Province "Astragalus polysaccharides inhibit liver fibrosis by regulating CD49a⁺NK cells (ZR2022QH111)."

Peer review information

Traditional Medicine Research thanks Hai-Jing Zhong, He Li and another anonymous reviewer for their contribution to the peer review of this paper.

Abbreviations

COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; ROS, reactive oxygen species; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; NF- κ B, nuclear factor kappa-B; TNF- α , tumor necrosis factor-alpha; TGF- β , transforming growth factor- β ; IL-6, interleukin-6; IL-1 β , interleukin-1 beta; MMP9, matrix metalloproteinase 9; HDAC2, histone deacetylase-2; PI3K, phosphoinositide-3-kinase; Nrf2, nuclear factor erythroid 2-related factor 2; CXCL, C-X-C motif chemokine ligand; NE, neutrophil elastase; MAPK, mitogen-activated protein kinase; EGF, epidermal growth factor; LPS, lipopolysaccharide; TLR4, toll-like receptor 4; JNK, c-Jun N-terminal kinase; SOD, superoxide dismutase; GSH, glutathione; GSH-Px, glutathione peroxidase; HO-1, haem oxygenase 1; MDA, malondialdehyde; SIRT1, silent information regulator 1; NAD⁺, nicotinamide adenine dinucleotide; GPX4, glutathione peroxidase 4; NADPH, nicotinamide adenine dinucleotide phosphate; GR, glucocorticoid receptor; CSE, cigarette smoke extract; I κ B, inhibitor kappa B; HBECS, human bronchial epithelial cells; TLRs, toll-like receptors; IRAK, interleukin-1 receptor-associated kinase; PKC, protein kinase C; NOX4, NADPH oxidase 4; TIMP, tissue inhibitors of metalloproteinase; EMT, epithelial-mesenchymal transition; α -SMA, alpha smooth muscle actin; ERK, extracellular regulated protein kinases; AKT, protein kinase B.

Citation


Shi PL, Zhang GX, Wang PY, Liu ZQ, Zheng BQ. Natural flavonoids for the treatment of chronic obstructive pulmonary

disease: An overview. *Tradit Med Res.* 2025;10(9):57. doi: 10.53388/TMR20241121001.

Executive editor: Xin-Yue Zhang.

Received: 22 November 2024; **Revised:** 01 January 2025;
Accepted: 27 February 2025; **Available online:** 03 March 2025.

© 2025 By Author(s). Published by TMR Publishing Group Limited. This is an open access article under the CC-BY license. (<https://creativecommons.org/licenses/by/4.0/>)



References

- World Health Organization. Global health estimates: leading causes of death. Cause specific mortality 2000–2019. <https://www.who.int/data/gho/>. Published 2019. Accessed May 08, 2024.
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med*. 2006;3(11):e442. Available at: <https://doi.org/10.1371/journal.pmed.0030442>
- Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. *Lancet*. 2022;399(10342):2227. Available at: [https://doi.org/10.1016/S0140-6736\(22\)00470-6](https://doi.org/10.1016/S0140-6736(22)00470-6)
- DeMeo DL. Sex and Gender Omic Biomarkers in Men and Women With COPD. *Chest*. 2021;160(1):104. Available at: <https://doi.org/10.1016/j.chest.2021.03.024>
- MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. *Respirology*. 2021;26(6):532. Available at: <https://doi.org/10.1111/resp.14041>
- Schaberg T, Klein U, Rau M, et al. Subpopulations of alveolar macrophages in smokers and nonsmokers: relation to the expression of CD11/CD18 molecules and superoxide anion production. *Am J Respir Crit Care Med*. 1995;151(5):1551. Available at: <https://doi.org/10.1164/ajrccm.151.5.7735614>
- Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. *Thorax*. 2001;56(6):432. Available at: <https://doi.org/10.1136/thx.56.6.432>
- van der Toorn M, Rezayat D, Kauffman HF, et al. Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2009;297(1):L109. Available at: <https://doi.org/10.1152/ajplung.90461.2008>
- Strange C. Alpha-1 Antitrypsin Deficiency Associated COPD. *Clin Chest Med*. 2020;41(3):339. Available at: <https://doi.org/10.1016/j.ccm.2020.05.003>
- Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. *Nature*. 2014;505(7483):412. Available at: <https://doi.org/10.1038/nature12807>
- Samsuzzaman Md, Uddin MdS, Shah MA, et al. Natural inhibitors on airway mucin: Molecular insight into the therapeutic potential targeting MUC5AC expression and production. *Life Sci*. 2019;231:116485. Available at: <https://doi.org/10.1016/j.lfs.2019.05.041>
- Shih YM, Chang YJ, Cooke MS, et al. Alkylating and oxidative stresses in smoking and non-smoking patients with COPD: Implications for lung carcinogenesis. *Free Radical Biol Med*. 2021;164:99. Available at: <https://doi.org/10.1016/j.freeradbiomed.2020.12.442>
- Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. *Curr Opin Pulm Med*. 2009;15(4):303. Available at: <https://doi.org/10.1097/MCP.0b013e32832c975a>
- Gorowiec MR, Borthwick LA, Parker SM, et al. Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-β1-dependent mechanism. *Free Radical Biol Med*. 2012;52(6):1024. Available at: <https://doi.org/10.1016/j.freeradbiomed.2011.12.020>
- Taggart C, Cervantes-Laurean D, Kim G, et al. Oxidation of either Methionine 351 or Methionine 358 in α1-Antitrypsin Causes Loss of Anti-neutrophil Elastase Activity. *J Biol Chem*. 2000;275(35):27258. Available at: [https://doi.org/10.1016/S0021-9258\(19\)61505-X](https://doi.org/10.1016/S0021-9258(19)61505-X)
- Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. *J Allergy Clin Immunol*. 2013;131(3):636. Available at: <https://doi.org/10.1016/j.jaci.2012.12.1564>
- To Y, Ito K, Kizawa Y, et al. Targeting Phosphoinositide-3-Kinase-δ with Theophylline Reverses Corticosteroid Insensitivity in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2010;182(7):897. Available at: <https://doi.org/10.1164/rccm.200906-0937OC>
- Yao HW, Rahman I. Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD. *Am J Physiol Lung Cell Mol Physiol*.

- 2012;303(7):L557. Available at: <https://doi.org/10.1152/ajplung.00175.2012>
19. Cheng SE, Lee IT, Lin CC, et al. Cigarette smoke particle-phase extract induces HO-1 expression in human tracheal smooth muscle cells: role of the c-Src/NADPH oxidase/MAPK/Nrf2 signaling pathway. *Free Radical Biol Med*. 2010;48(10):1410. Available at: <https://doi.org/10.1016/j.freeradbiomed.2010.02.026>
 20. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. *Lancet*. 2011;378(9795):1015. Available at: [https://doi.org/10.1016/S0140-6736\(11\)60988-4](https://doi.org/10.1016/S0140-6736(11)60988-4)
 21. Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. *PLoS Med*. 2004;1(1):e8. Available at: <https://doi.org/10.1371/journal.pmed.0010008>
 22. Majo J, Ghezzi H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. *Eur Respir J*. 2001;17(5):946. Available at: <https://doi.org/10.1183/09031936.01.17509460>
 23. Lagente V, Manoury B, Nénan S, et al. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. *Braz J Med Biol Res*. 2005;38(10):1521. Available at: <https://doi.org/10.1590/S0100-879X2005001000009>
 24. Sng JJ, Prazakova S, Thomas PS, et al. MMP-8, MMP-9 and Neutrophil Elastase in Peripheral Blood and Exhaled Breath Condensate in COPD. *COPD*. 2017;14(2):238. Available at: <https://doi.org/10.1080/15412555.2016.1249790>
 25. Burgel PR. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. *Thorax*. 2004;59(11):992. Available at: <https://doi.org/10.1136/thx.2003.018879>
 26. Shao MXG, Nakanaga T, Nadel JA. Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor- α -converting enzyme in human airway epithelial (NCI-H292) cells. *Am J Physiol Lung Cell Mol Physiol*. 2004;287(2):L420. Available at: <https://doi.org/10.1152/ajplung.00019.2004>
 27. Chen P, Parks WC. Role of matrix metalloproteinases in epithelial migration. *J Cell Biochem*. 2009;108(6):1233. Available at: <https://doi.org/10.1002/jcb.22363>
 28. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. *PLoS One*. 2007;2(5):e482. Available at: <https://doi.org/10.1371/journal.pone.0000482>
 29. Al-Tamari HM, Dabral S, Schmall A, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. *EMBO Mol Med*. 2017;10(2):276. Available at: <https://doi.org/10.15252/emmm.201606261>
 30. Wang H, Yang T, Wang T, et al. Phloretin attenuates mucus hypersecretion and airway inflammation induced by cigarette smoke. *Int Immunopharmacol*. 2018;55:112. Available at: <https://doi.org/10.1016/j.intimp.2017.12.009>
 31. Birru RL, Bein K, Bondarchuk N, et al. Antimicrobial and Anti-Inflammatory Activity of Apple Polyphenol Phloretin on Respiratory Pathogens Associated With Chronic Obstructive Pulmonary Disease. *Front Cell Infect Microbiol*. 2021;11:652944. Available at: <https://doi.org/10.3389/fcimb.2021.652944>
 32. Yu D, Liu X, Zhang G, et al. Isoliquiritigenin Inhibits Cigarette Smoke-Induced COPD by Attenuating Inflammation and Oxidative Stress via the Regulation of the Nrf2 and NF- κ B Signaling Pathways. *Front Pharmacol*. 2018;9:1001. Available at: <https://doi.org/10.3389/fphar.2018.01001>
 33. Wang Y, Xue C, Dong F, et al. Hydroxysafflor Yellow A Attenuates Small Airway Remodeling in a Rat Model of Chronic Obstructive Pulmonary Disease. *Biol Pharm Bull*. 2014;37(10):1591. Available at: <https://doi.org/10.1248/bpb.b14-00198>
 34. Guo X, Zheng M, Pan R, et al. Hydroxysafflor Yellow A Suppresses Platelet Activating Factor-Induced Activation of Human Small Airway Epithelial Cells. *Front Pharmacol*. 2018;9:859. Available at: <https://doi.org/10.3389/fphar.2018.00859>
 35. Jin M, Xue C, Wang Y, et al. Protective Effect of Hydroxysafflor Yellow A on Inflammatory Injury in Chronic Obstructive Pulmonary Disease Rats. *Chin J Integr Med*. 2019;25(10):750. Available at: <https://doi.org/10.1007/s11655-018-2577-2>
 36. Li BS, Zhu RZ, Lim SH, et al. Apigenin Alleviates Oxidative Stress-Induced Cellular Senescence via Modulation of the SIRT1-NAD⁺-CD38 Axis. *Am J Chin Med*. 2021;49(5):1235. Available at: <https://doi.org/10.1142/S0192415X21500592>
 37. Li J, Tong D, Liu J, et al. Oroxylin A attenuates cigarette smoke-induced lung inflammation by activating Nrf2. *Int Immunopharmacol*. 2016;40:524. Available at: <https://doi.org/10.1016/j.intimp.2016.10.011>
 38. Liu L, Zhang Y, Wang L, et al. Scutellarein alleviates chronic obstructive pulmonary disease through inhibition of ferroptosis by chelating iron and interacting with arachidonate 15-lipoxygenase. *Phytother Res*. 2023;37(10):4587. Available at: <https://doi.org/10.1002/ptr.7928>
 39. Ganesan S, Faris AN, Comstock AT, et al. Quercetin prevents progression of disease in elastase/LPS-exposed mice by negatively regulating MMP expression. *Respir Res*. 2010;11(1):131. Available at: <https://doi.org/10.1186/1465-9921-11-131>
 40. Mitani A, Azam A, Vuppasetty C, et al. Quercetin restores corticosteroid sensitivity in cells from patients with chronic obstructive pulmonary disease. *Exp Lung Res*. 2017;43(9-10):417. Available at: <https://doi.org/10.1080/01902148.2017.1393707>
 41. Farazuddin M, Mishra R, Jing Y, et al. Quercetin prevents rhinovirus-induced progression of lung disease in mice with COPD phenotype. *PLoS One*. 2018;13(7):e0199612. Available at: <https://doi.org/10.1371/journal.pone.0199612>
 42. Wei P, Chen ZB, Wang CE, et al. Protective function and mechanism of quercetin in chronic obstructive pulmonary disease. *Chin J Immunol*. 2019;35(21):2570.
 43. Han MK, Barreto TA, Martinez FJ, et al. Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. *BMJ Open Res*. 2020;7(1):e000392. Available at: <https://doi.org/10.1136/bmjresp-2018-000392>
 44. Wu XP, Tao YZ, Liu L, et al. Quercetin reduces airway mucus hypersecretion in rats based on EGFR signaling pathway. *Chin J Immunol*. 2022;38(8):940. Available at: <https://doi.org/10.3969/j.issn.1000-484X.2022.08.008>
 45. da Silva Araújo NP, de Matos NA, Oliveira M, et al. Quercetin Improves Pulmonary Function and Prevents Emphysema Caused by Exposure to Cigarette Smoke in Male Mice. *Antioxidants (Basel)*. 2022;11(2):181. Available at: <https://doi.org/10.3390/antiox11020181>
 46. McCluskey ES, Liu N, Pandey A, et al. Quercetin improves epithelial regeneration from airway basal cells of COPD patients. *Res Sq*. 2023;2023. Available at: <https://doi.org/10.21203/rs.3.rs-3185241/v1>
 47. Lee S, Ro H, In HJ, et al. Fisetin inhibits TNF- α /NF- κ B-induced IL-8 expression by targeting PKC δ in human airway epithelial cells. *Cytokine*. 2018;108:247. Available at: <https://doi.org/10.1016/j.cyto.2018.01.004>
 48. Hussain T, Al-Attas OS, Alamery S, et al. The plant flavonoid, fisetin alleviates cigarette smoke-induced oxidative stress, and inflammation in Wistar rat lungs. *J Food Biochem*.

- 2019;43(8):e12962. Available at: <https://doi.org/10.1111/jfbc.12962>
49. Chen M, Chen Z, Huang D, et al. Myricetin inhibits TNF- α -induced inflammation in A549 cells via the SIRT1/NF- κ B pathway. *Pulm Pharmacol Ther.* 2020;65:102000. Available at: <https://doi.org/10.1016/j.pupt.2021.102000>
 50. Lee H, Jung KH, Lee H, et al. Casticin, an active compound isolated from Vitex Fructus, ameliorates the cigarette smoke-induced acute lung inflammatory response in a murine model. *Int Immunopharmacol.* 2015;28(2):1097. Available at: <https://doi.org/10.1016/j.intimp.2015.07.041>
 51. Li J, Qiu C, Xu P, et al. Casticin Improves Respiratory Dysfunction and Attenuates Oxidative Stress and Inflammation via Inhibition of NF- κ B in a Chronic Obstructive Pulmonary Disease Model of Chronic Cigarette Smoke-Exposed Rats. *Drug Des Devel Ther.* 2020;14:5019. Available at: <https://doi.org/10.2147/DDDT.S277126>
 52. Lu LJ, Tian H, Zheng Y, et al. Effects of casticin on Lipopolysaccharide-induced BEAS-2B cell damage and NF- κ B-KEAP1-NRF2/ARE pathway. *Chin J Immunol.* 2023;40(3):546. Available at: <https://doi.org/10.3969/j.issn.1000-484X.2024.03.018>
 53. Lu LJ, Tian H, Zheng Y, et al. Study on the effect of casticin on oxidative stress injury in BEAS-2B cells. *Chin J Clin Pharmacol.* 2023;39(1):42. Available at: <https://doi.org/10.13699/j.cnki.1001-6821.2023.01.009>
 54. Li MF, Wang HF, Lu Y, et al. Luteolin suppresses inflammation and oxidative stress in chronic obstructive pulmonary disease through inhibition of the NOX4-mediated NF- κ B signaling pathway. *Immun Inflamm Dis.* 2023;11(4):e820. Available at: <https://doi.org/10.1002/iid3.820>
 55. Zhou L, Jian T, Wan Y, et al. Luteolin Alleviates Oxidative Stress in Chronic Obstructive Pulmonary Disease Induced by Cigarette Smoke via Modulation of the TRPV1 and CYP2A13/NRF2 Signaling Pathways. *Int J Mol Sci.* 2023;25(1):369. Available at: <https://doi.org/10.3390/ijms25010369>
 56. Luo YL, Zhang CC, Li PB, et al. Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke. *Int Immunopharmacol.* 2012;13(3):301. Available at: <https://doi.org/10.1016/j.intimp.2012.04.019>
 57. Liu J, Yao J, Zhang J. Naringenin attenuates inflammation in chronic obstructive pulmonary disease in cigarette smoke induced mouse model and involves suppression of NF- κ B. *J Microbiol Biotechnol.* 2018;2018.
 58. Chen Z, Wu H, Fan W, et al. Naringenin suppresses BEAS-2B-derived extracellular vesicular cargoes disorder caused by cigarette smoke extract thereby inhibiting M1 macrophage polarization. *Front Immunol.* 2022;13:930476. Available at: <https://doi.org/10.3389/fimmu.2022.930476>
 59. Wang S, He N, Xing H, et al. Function of hesperidin alleviating inflammation and oxidative stress responses in COPD mice might be related to SIRT1/PGC-1 α /NF- κ B signaling axis. *J Recept Signal Transduct.* 2020;40(4):388. Available at: <https://doi.org/10.1080/10799893.2020.1738483>
 60. Zhou L, Gu W, Kui F, et al. The mechanism and candidate compounds of aged citrus peel (chenpi) preventing chronic obstructive pulmonary disease and its progression to lung cancer. *Food Nutr Res.* 2021;65:7526. Available at: <https://doi.org/10.29219/fnr.v65.7526>
 61. Liu X, Ma Y, Luo L, et al. Dihydroquercetin suppresses cigarette smoke induced ferroptosis in the pathogenesis of chronic obstructive pulmonary disease by activating Nrf2-mediated pathway. *Phytomedicine.* 2022;96:153894. Available at: <https://doi.org/10.1016/j.phymed.2021.153894>
 62. Liu X, Ma Y, Luo L, et al. Taxifolin ameliorates cigarette smoke-induced chronic obstructive pulmonary disease via inhibiting inflammation and apoptosis. *Int Immunopharmacol.* 2023;115:109577. Available at: <https://doi.org/10.1016/j.intimp.2022.109577>
 63. Zeng LX, Dong JC, Yu WQ, et al. Baicalin attenuates inflammation by inhibiting NF- κ B activation in cigarette smoke induced inflammatory models. *Pulm Pharmacol Ther.* 2010;23(5):411. Available at: <https://doi.org/10.1016/j.pupt.2010.05.004>
 64. Li L, Bao H, Wu J, et al. Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: A possible role for HDAC2 activity. *Int Immunopharmacol.* 2012;13(1):15. Available at: <https://doi.org/10.1016/j.intimp.2012.03.001>
 65. Wang G, Mohammadtursun N, Lv Y, et al. Baicalin Exerts Anti-Airway Inflammation and Anti-Remodelling Effects in Severe Stage Rat Model of Chronic Obstructive Pulmonary Disease. *Evid Based Complement Alternat Med.* 2018;2018:7591348. Available at: <https://doi.org/10.1155/2018/7591348>
 66. Hao DX, Li YS, Shi J, et al. Baicalin alleviates chronic obstructive pulmonary disease through regulation of HSP72-mediated JNK pathway. *Mol Med.* 2021;27(1):53. Available at: <https://doi.org/10.1186/s10020-021-00309-z>
 67. Zhang H, Liu BJ, Jiang S, et al. Baicalin ameliorates cigarette smoke-induced airway inflammation in rats by modulating HDAC2/NF- κ B/PAI-1 signalling. *Pulm Pharmacol Ther.* 2021;70:102061. Available at: <https://doi.org/10.1016/j.pupt.2021.102061>
 68. Xiao XF, Zhao SL, Wang W, et al. Baicalin upregulates miR-4451 effect on lipopolysaccharide-induced apoptosis and inflammatory response in HBE16 cells. *Lishizhen Med Res.* 2022;33(7):1630.
 69. Zhang Y, Zhang CL, Liu Y, et al. Effects of baicalin on expression of mucin 5AC and cystic fibrosis transmembrane conductance regulator in airway epithelium through NF- κ B signaling pathway. *J Army Med Univ.* 2022;44(5):441. Available at: <https://doi.org/10.16016/j.2097-0927.202109016>
 70. Ju J, Li Z, Shi Q. Baicalin Inhibits Inflammation in Rats with Chronic Obstructive Pulmonary Disease by the TLR2/MYD88/NF- κ Bp65 Signaling Pathway. *Evid Based Complement Alternat Med.* 2022;2022:7273387. Available at: <https://doi.org/10.1155/2022/7273387>
 71. Jing X, Huo J, Li L, et al. Baicalin Relieves Airway Inflammation in COPD by Inhibiting miR-125a. *Appl Biochem Biotechnol.* 2024;196(6):3374. Available at: <https://doi.org/10.1007/s12010-023-04671-y>
 72. Kim YH, Kang MK, Lee EJ, et al. Astragaloside Inhibits Cigarette Smoke-Induced Pulmonary Thrombosis and Alveolar Inflammation and Disrupts PAR Activation and Oxidative Stress-Responsive MAPK-Signaling. *Int J Mol Sci.* 2021;22(7):3692. Available at: <https://doi.org/10.3390/ijms22073692>
 73. Hu L, Liu F, Li L, et al. Effects of icariin on cell injury and glucocorticoid resistance in BEAS-2B cells exposed to cigarette smoke extract. *Exp Ther Med.* 2020;20(1):283. Available at: <https://doi.org/10.3892/etm.2020.8702>
 74. Lu R, Xu K, Qin Y, et al. Network Pharmacology and Experimental Validation to Reveal Effects and Mechanisms of Icariin Combined with Nobiletin against Chronic Obstructive Pulmonary Diseases. *Evid Based Complement Alternat Med.* 2022;2022:4838650. Available at: <https://doi.org/10.1155/2022/4838650>
 75. Li QP, Zhang HY, Yan XP, et al. Up-regulation of PPAR- γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation. *Pulm Pharmacol Ther.*

- 2023;79:102197. Available at: <https://doi.org/10.1016/j.pupt.2023.102197>
76. Guan Y, Li FF, Hong L, et al. Protective effects of liquiritin apioside on cigarette smoke-induced lung epithelial cell injury. *Fundam Clin Pharmacol*. 2011;26(4):473. Available at: <https://doi.org/10.1111/j.1472-8206.2011.00956.x>
 77. Song WY, Song YS, Ryu HW, et al. Tiliarin Inhibits MUC5AC Expression Mediated Via Down-Regulation of EGFR-MEK-ERK-Sp1 Signaling Pathway in NCI-H292 Human Airway Cells. *J Microbiol Biotechnol*. 2017;27(1):49. Available at: <https://doi.org/10.4014/jmb.1610.10012>
 78. Kim SH, Hong JH, Yang WK, et al. Herbal Combinational Medication of Glycyrrhiza glabra, Agastache rugosa Containing Glycyrrhizic Acid, Tiliarin Inhibits Neutrophilic Lung Inflammation by Affecting CXCL2, Interleukin-17/STAT3 Signal Pathways in a Murine Model of COPD. *Nutrients*. 2020;12(4):926. Available at: <https://doi.org/10.3390/nu12040926>
 79. Luo YL, Li PB, Zhang CC, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. *Inflamm Res*. 2013;62(12):1053. Available at: <https://doi.org/10.1007/s00011-013-0664-6>
 80. Xue Z, Li A, Zhang X, et al. Amelioration of PM2.5-induced lung toxicity in rats by nutritional supplementation with biochanin A. *Ecotoxicol Environ Saf*. 2020;202:110878. Available at: <https://doi.org/10.1016/j.ecoenv.2020.110878>
 81. Wang L, Jiang W, Wang J, et al. Puerarin inhibits FUNDC1-mediated mitochondrial autophagy and CSE-induced apoptosis of human bronchial epithelial cells by activating the PI3K/AKT/mTOR signaling pathway. *Aging (Albany NY)*. 2022;14(3):1253. Available at: <https://doi.org/10.18632/aging.203317>
 82. Pan XJ, Fan JQ, Xia GQ. Puerarin inhibits alveolar epithelial cell apoptosis in rats with chronic obstructive pulmonary disease by regulating PINK1-parkin signaling pathway-mediated mitophagy. *Chin J Pathophysiol*. 2022;38(10):1833.
 83. Li XM, Jiang XH, Zeng RH, et al. Formononetin attenuates cigarette smoke-induced COPD in mice by suppressing inflammation, endoplasmic reticulum stress, and apoptosis in bronchial epithelial cells via AhR/CYP1A1 and AKT/mTOR signaling pathways. *Phytother Res*. 2024;38(3):1278. Available at: <https://doi.org/10.1002/ptr.8104>
 84. Tian X, Xue Y, Xie G, et al. (-)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD. *Toxicol Appl Pharmacol*. 2021;429:115674. Available at: <https://doi.org/10.1016/j.taap.2021.115674>
 85. Lakshmi SP, Reddy AT, Kodihela LD, et al. Epigallocatechin gallate diminishes cigarette smoke-induced oxidative stress, lipid peroxidation, and inflammation in human bronchial epithelial cells. *Life Sci*. 2020;259:118260. Available at: <https://doi.org/10.1016/j.lfs.2020.118260>
 86. Park JW, Shin NR, Shin IS, et al. Silibinin Inhibits Neutrophilic Inflammation and Mucus Secretion Induced by Cigarette Smoke via Suppression of ERK-SP1 Pathway. *Phytother Res*. 2016;30(12):1926. Available at: <https://doi.org/10.1002/ptr.5686>
 87. Ko JW, Shin NR, Park SH, et al. Silibinin inhibits the fibrotic responses induced by cigarette smoke via suppression of TGF- β 1/Smad 2/3 signaling. *Food Chem Toxicol*. 2017;106(Pt A):424. Available at: <https://doi.org/10.1016/j.fct.2017.06.016>
 88. Li DD, Xu D, Wang T, et al. Silymarin Attenuates Airway Inflammation Induced by Cigarette Smoke in Mice. *Inflammation*. 2014;38(2):871. Available at: <https://doi.org/10.1007/s10753-014-9996-9>
 89. Li D, Hu J, Wang T, et al. Silymarin attenuates cigarette smoke extract-induced inflammation via simultaneous inhibition of autophagy and ERK/p38 MAPK pathway in human bronchial epithelial cells. *Sci Rep*. 2016;6:37751. Available at: <https://doi.org/10.1038/srep37751>
 90. Tao Z, Bai S, Wu G, et al. Therapeutic effect of ginkgetin on smoke-induced airway inflammation by down-regulating the c/EBP β signaling pathway and CCL2 expression. *J Ethnopharmacol*. 2024;331:118284. Available at: <https://doi.org/10.1016/j.jep.2024.118284>
 91. Chen XL, Geng DS. Effect of Total Flavonoids from Nigella glandulifera on Inflammation of Chronic Obstructive Pulmonary Disease Model Rats and Its Mechanism. *Chin Pharm J*. 2014;49(4):294.
 92. Ren QC, Li XH, Li QY, et al. Total flavonoids from sea buckthorn ameliorates lipopolysaccharide/cigarette smoke-induced airway inflammation. *Phytother Res*. 2019;33(8):2102. Available at: <https://doi.org/10.1002/ptr.6404>
 93. Yang JM, Wang HZ, Shi QX, et al. Effect and Mechanism of Total Flavonoids from Scutellaria Baicalensis Georgi in the Inflammation and Oxidative Stress in Rats with Chronic Obstructive Pulmonary Disease. *Chin Pharm*. 2020;23(6):1069.
 94. Jian T, Chen J, Ding X, et al. Flavonoids isolated from loquat (Eriobotrya japonica) leaves inhibit oxidative stress and inflammation induced by cigarette smoke in COPD mice: the role of TRPV1 signaling pathways. *Food Funct*. 2020;11(4):3516. Available at: <https://doi.org/10.1039/C9FO02921D>
 95. Li Y, Zhao J, Shao H, et al. Preventive effect of total flavonoids of Trollius altaicus on a chronic obstructive pulmonary disease rat model based on the TLR4/NF- κ B pathway. *Ann Transl Med*. 2022;10(4):222. Available at: <https://doi.org/10.21037/atm-22-331>
 96. Ding HD, Wu RN, Ao M, et al. Protective effect of nasturtium total flavonoids on emphysema in elderly mice and its effect on the expression of p38MAPK signaling pathway in lung tissue. *Chin J Gerontol*. 2023;43(7):1721. Available at: <https://doi.org/10.3969/j.issn.1005-9202.2023.07.048>
 97. Wang C, Chen F, Hu KS, et al. Antioxidant Protective Effect and Mechanism of Total Flavonoids from Dandelion on Cigarette Smoke – Induced Chronic Obstructive Pulmonary Disease. *Int J Geriatr*. 2023;44(3):257. Available at: <https://doi.org/10.3969/j.issn.1674-7593.2023.03.001>
 98. Repine JE, Bast A, Lankhorst I. Oxidative Stress in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 1997;156(2 Pt 1):341. Available at: <https://doi.org/10.1164/ajrccm.156.2.9611013>
 99. Van Eeden SF, Sin DD. Oxidative Stress in Chronic Obstructive Pulmonary Disease: A Lung and Systemic Process. *Can Respir J*. 2013;20(1):27. Available at: <https://doi.org/10.1155/2013/509130>
 100. Suzuki M, Betsuyaku T, Ito Y, et al. Down-Regulated NF-E2-Related Factor 2 in Pulmonary Macrophages of Aged Smokers and Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Cell Mol Biol*. 2008;39(6):673. Available at: <https://doi.org/10.1165/rcmb.2007-0424OC>
 101. Eurlings IMJ, Reynaert NL, van de Wetering C, et al. Involvement of c-Jun N-Terminal Kinase in TNF- α -Driven Remodeling. *Am J Respir Cell Mol Biol*. 2017;56(3):393. Available at: <https://doi.org/10.1165/rcmb.2015-0195OC>
 102. Johnson JL, Moore EE, Tamura DY, et al. Interleukin-6 Augments Neutrophil Cytotoxic Potential via Selective Enhancement of Elastase Release. *J Surg Res*. 1998;76(1):91. Available at: <https://doi.org/10.1006/jsre.1998.5295>
 103. Perkins ND. Integrating cell-signalling pathways with NF- κ B and IKK function. *Nat Rev Mol Cell Biol*. 2007;8(1):49.

- Available at:
<https://doi.org/10.1038/nrm2083>
104. Schuliga M. NF-kappaB Signaling in Chronic Inflammatory Airway Disease. *Biomolecules*. 2015;5(3):1266. Available at: <https://doi.org/10.3390/biom5031266>
 105. Lora JM, Zhang DM, Liao SM, et al. Tumor Necrosis Factor- α Triggers Mucus Production in Airway Epithelium through an I κ B Kinase β -dependent Mechanism. *J Biol Chem*. 2005;280(43):36510. Available at: <https://doi.org/10.1074/jbc.M507977200>
 106. Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. *Cell*. 2020;180(6):1044. Available at: <https://doi.org/10.1016/j.cell.2020.02.041>
 107. Takeuchi O, Takeda K, Hoshino K, et al. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. *Int Immunol*. 2000;12(1):113. Available at: <https://doi.org/10.1093/intimm/12.1.113>
 108. Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an Antiinflammatory and Antiaging Protein, Is Decreased in Lungs of Patients with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2008;177(8):861. Available at: <https://doi.org/10.1164/rccm.200708-1269OC>
 109. Yao H, Chung S, Hwang J, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. *J Clin Invest*. 2012;122(6):2032. Available at: <https://doi.org/10.1172/JCI60132>
 110. Lee MR, Dominguez C. MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38 α Protein. *Curr Med Chem*. 2005;12(25):2979. Available at: <https://doi.org/10.2174/092986705774462914>
 111. Huang CP, Xie MY, He XH, et al. Activity of sputum p38 MAPK is correlated with airway inflammation and reduced FEV1 in COPD patients. *Med Sci Monit*. 2013;19:1229. Available at: <https://doi.org/10.12659/MSM.889880>
 112. Wang B, Lim DJ, Han J, et al. Novel Cytoplasmic Proteins of Nontypeable Haemophilus influenzae Up-regulate Human MUC5AC Mucin Transcription via a Positive p38 Mitogen-activated Protein Kinase Pathway and a Negative Phosphoinositide 3-Kinase-Akt Pathway. *J Biol Chem*. 2002;277(2):949. Available at: <https://doi.org/10.1074/jbc.M107484200>
 113. Chang C, Zhu H, Shen N, et al. Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes before and after Treatment of AECOPD, a Longitudinal and Cross-sectional Study. *COPD*. 2014;12(1):19. Available at: <https://doi.org/10.3109/15412555.2014.898043>
 114. Mahmood M, Sohal SS, Shukla SD, et al. Epithelial mesenchymal transition in smokers: large versus small airways and relation to airflow obstruction. *Int J Chron Obstruct Pulmon Dis*. 2015;10:1515. Available at: <https://doi.org/10.2147/COPD.S81032>
 115. Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive pathway map of epidermal growth factor receptor signaling. *Mol Syst Biol*. 2005;1:2005. Available at: <https://doi.org/10.1038/msb4100014>
 116. Palosaari H, Pennington CJ, Larmas M, et al. Expression profile of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in mature human odontoblasts and pulp tissue. *Eur J Oral Sci*. 2003;111(2):117. Available at: <https://doi.org/10.1034/j.1600-0722.2003.00026.x>
 117. Antunes MA, Rocco PRM. Elastase-induced pulmonary emphysema: insights from experimental models. *An Acad Bras Ciênc*. 2011;83(4):1385. Available at: <https://doi.org/10.1590/S0001-37652011005000039>
 118. Soltani A, Walters EH, Reid D, et al. Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:2359. Available at: <https://doi.org/10.2147/COPD.S113176>
 119. Mahmood MQ, Reid D, Ward C, et al. Transforming growth factor (TGF) β 1 and Smad signalling pathways: A likely key to EMT-associated COPD pathogenesis. *Respirology*. 2017;22(1):133. Available at: <https://doi.org/10.1111/resp.12882>
 120. Park JW, Ryter SW, Choi AMK. Functional Significance of Apoptosis in Chronic Obstructive Pulmonary Disease. *COPD*. 2007;4(4):347. Available at: <https://doi.org/10.1080/15412550701603775>
 121. Hodge S, Hodge G, Holmes M, et al. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. *Eur Respir J*. 2005;25(3):447. Available at: <https://doi.org/10.1183/09031936.05.00077604>
 122. Li J, Cao F, Yin H, et al. Ferroptosis: past, present and future. *Cell Death Dis*. 2020;11(2):88. Available at: <https://doi.org/10.1038/s41419-020-2298-2>
 123. Yoshida M, Minagawa S, Araya J, et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis. *Nat Commun*. 2019;10(1):3145. Available at: <https://doi.org/10.1038/s41467-019-10991-7>
 124. Wang Y, Xia S. Relationship Between ACSL4-Mediated Ferroptosis and Chronic Obstructive Pulmonary Disease. *Int J Chron Obstruct Pulmon Dis*. 2023;18:99. Available at: <https://doi.org/10.2147/COPD.S391129>
 125. Zhang ZX, Fu CL, Liu JX, et al. Hypermethylation of the Nrf2 Promoter Induces Ferroptosis by Inhibiting the Nrf2-GPX4 Axis in COPD. *Int J Chron Obstruct Pulmon Dis*. 2021;16:3347. Available at: <https://doi.org/10.2147/COPD.S340113>
 126. Wang L, Mou L, Guan S, et al. Isoliquiritigenin induces neurodevelopmental-toxicity and anxiety-like behavior in zebrafish larvae. *Comp Biochem Physiol C Toxicol Pharmacol*. 2023;266:109555. Available at: <https://doi.org/10.1016/j.cbpc.2023.109555>
 127. Liu Z, Li C, Li M, et al. The subchronic toxicity of hydroxysafflor yellow A of 90 days repeatedly intraperitoneal injections in rats. *Toxicology*. 2004;203(1-3):139. Available at: <https://doi.org/10.1016/j.tox.2004.06.007>
 128. Wu M, Zheng N, Zhan X, et al. Icariin induces developmental toxicity via thyroid hormone disruption in zebrafish larvae. *Food Chem Toxicol*. 2023;182:114155. Available at: <https://doi.org/10.1016/j.fct.2023.114155>
 129. Wu J, Zhang X, Zhang B. Efficacy and safety of puerarin injection in treatment of diabetic peripheral neuropathy: a systematic review and Meta-analysis of randomized controlled trials. *J Tradit Chin Med*. 2014;34(4):401. Available at: [https://doi.org/10.1016/S0254-6272\(15\)30039-X](https://doi.org/10.1016/S0254-6272(15)30039-X)
 130. Pingale TD, Gupta GL. Acute and sub-acute toxicity study reveals no detrimental effect of formononetin in mice upon repeated i.p. dosing. *Toxicol Mech Methods*. 2023;33(8):688. Available at: <https://doi.org/10.1080/15376516.2023.2234026>
 131. Li YY, Lu XY, Sun JL, et al. Potential hepatic and renal toxicity induced by the biflavonoids from Ginkgo biloba. *Chin J Nat Med*. 2019;17(9):672. Available at: [https://doi.org/10.1016/S1875-5364\(19\)30081-0](https://doi.org/10.1016/S1875-5364(19)30081-0)
 132. Wedzicha JA. Causes of Death in Smokers: Implications for Chronic Obstructive Pulmonary Disease Management across Disease Severity. *Am J Respir Crit Care Med*. 2023;208(4):354. Available at: <https://doi.org/10.1164/rccm.202306-1065ED>
 133. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. *Lancet Respir Med*. 2022;10(5):497. Available at: [https://doi.org/10.1016/S2213-2600\(21\)00506-3](https://doi.org/10.1016/S2213-2600(21)00506-3)

134. Mart MF, Peebles RS Jr. Asthma-chronic obstructive pulmonary disease overlap syndrome. *Curr Opin Immunol.* 2020;66:161. Available at: <https://doi.org/10.1016/j.coi.2020.10.006>
135. Shah AJ, Quek E, Alqahtani JS, et al. Cardiovascular outcomes in patients with COPD-O SA overlap syndrome: A systematic review and meta-analysis. *Sleep Med Rev.* 2022;63:101627. Available at: <https://doi.org/10.1016/j.smrv.2022.101627>
136. Barnes PJ. Oxidative stress-based therapeutics in COPD. *Redox Biol.* 2020;33:101544. Available at: <https://doi.org/10.1016/j.redox.2020.101544>
137. Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. *Eur Respir J.* 2019;54(2):1900651. Available at: <https://doi.org/10.1183/13993003.00651-2019>
138. Yun JH, Morrow J, Owen CA, et al. Transcriptomic Analysis of Lung Tissue from Cigarette Smoke-Induced Emphysema Murine Models and Human Chronic Obstructive Pulmonary Disease Show Shared and Distinct Pathways. *Am J Respir Cell Mol Biol.* 2017;57(1):47. Available at: <https://doi.org/10.1165/rcmb.2016-0328OC>
139. Hou HH, Cheng SL, Chung KP, et al. Elastase induces lung epithelial cell autophagy through placental growth factor. *Autophagy.* 2014;10(9):1509. Available at: <https://doi.org/10.4161/auto.29190>
140. Shen N, Wang T, Gan Q, et al. Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity. *Food Chem.* 2022;383:132531. Available at: <https://doi.org/10.1016/j.foodchem.2022.132531>
141. Zeng X, Xi Y, Jiang W. Protective roles of flavonoids and flavonoid-rich plant extracts against urolithiasis: A review. *Crit Rev Food Sci Nutr.* 2019;59(13):2125. Available at: <https://doi.org/10.1080/10408398.2018.1439880>
142. Hirayama F, Lee AH, Binns CW, et al. Dietary intake of isoflavones and polyunsaturated fatty acids associated with lung function, breathlessness and the prevalence of chronic obstructive pulmonary disease: Possible protective effect of traditional Japanese diet. *Mol Nutr Food Res.* 2010;54(7):909. Available at: <https://doi.org/10.1002/mnfr.200900316>
143. Bondonno NP, Parmenter BH, Dalgaard F, et al. Flavonoid intakes inversely associate with COPD in smokers. *Eur Respir J.* 2022;60(2):2102604. Available at: <https://doi.org/10.1183/13993003.02604-2021>
144. Hogg JC, Timens W. The Pathology of Chronic Obstructive Pulmonary Disease. *Annu Rev Pathol Mech Dis.* 2009;4:435. Available at: <https://doi.org/10.1146/annurev.pathol.4.110807.092145>
145. Barnes PJ, Burney PGJ, Silverman EK, et al. Chronic obstructive pulmonary disease. *Nat Rev Dis Primers.* 2015;1:15076. Available at: <https://doi.org/10.1038/nrdp.2015.76>
146. Polverino F, Sin DD. Type 2 airway inflammation in COPD. *Eur Respir J.* 2024;63(5):2400150. Available at: <https://doi.org/10.1183/13993003.00150-2024>
147. David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. *Thorax.* 2020;76(2):188. Available at: <https://doi.org/10.1136/thoraxjnl-2020-215167>
148. Burgess JK, Weiss DJ, Westergren-Thorsson G, et al. Extracellular Matrix as a Driver of Chronic Lung Diseases. *Am J Respir Cell Mol Biol.* 2024;70(4):239. Available at: <https://doi.org/10.1165/rcmb.2023-0176PS>
149. Feng YY, Li M, Yangzhong XT, et al. Pyroptosis in inflammation-related respiratory disease. *J Physiol Biochem.* 2022;78(4):721. Available at: <https://doi.org/10.1007/s13105-022-00909-1>
150. Cao X, Wang Y, Chen Y, et al. Advances in traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease. *J Ethnopharmacol.* 2023;307:116229. Available at: <https://doi.org/10.1016/j.jep.2023.116229>
151. Kirkham PA, Barnes PJ. Oxidative Stress in COPD. *Chest.* 2013;144(1):266. Available at: <https://doi.org/10.1378/chest.12-2664>
152. McGuinness A, Sapey E. Oxidative Stress in COPD: Sources, Markers, and Potential Mechanisms. *J Clin Med.* 2017;6(2):21. Available at: <https://doi.org/10.3390/jcm6020021>
153. Huang H, Feng H, Zhuge D. M1 Macrophage Activated by Notch Signal Pathway Contributed to Ventilator-Induced Lung Injury in Chronic Obstructive Pulmonary Disease Model. *J Surg Res.* 2019;244:358. Available at: <https://doi.org/10.1016/j.jss.2019.06.060>
154. Takiguchi H, Yang CX, Yang CWT, et al. Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures. *Sci Rep.* 2021;11(1):8282. Available at: <https://doi.org/10.1038/s41598-021-87720-y>
155. Wang R, Ramos C, Joshi I, et al. Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides. *Am J Physiol.* 1999;277(6):L1158. Available at: <https://doi.org/10.1152/ajplung.1999.277.6.L1158>
156. Waghray M, Cui Z, Horowitz JC, et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. *FASEB J.* 2005;19(7):854. Available at: <https://doi.org/10.1096/fj.04-2882fje>
157. Van Pottelberge GR, Bracke KR, Joos GF, et al. The Role of Dendritic Cells in the Pathogenesis of COPD: Liaison Officers in the Front Line. *COPD.* 2009;6(4):284. Available at: <https://doi.org/10.1080/15412550903049124>
158. Adler KB, Holden-Stauffer WJ, Repine JE. Oxygen metabolites stimulate release of high-molecular-weight glycoconjugates by cell and organ cultures of rodent respiratory epithelium via an arachidonic acid-dependent mechanism. *J Clin Invest.* 1990;85(1):75. Available at: <https://doi.org/10.1172/JCI114436>
159. Abed DA, Goldstein M, Albanyan H, et al. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. *Acta Pharm Sin B.* 2015;5(4):285. Available at: <https://doi.org/10.1016/j.apsb.2015.05.008>
160. Tonelli C, Chio IIC, Tuveson DA. Transcriptional Regulation by Nrf2. *Antioxid Redox Signal.* 2018;29(17):1727. Available at: <https://doi.org/10.1089/ars.2017.7342>
161. Bormann T, Maus R, Stolper J, et al. Role of matrix metalloprotease-2 and MMP-9 in experimental lung fibrosis in mice. *Respir Res.* 2022;23(1):180. Available at: <https://doi.org/10.1186/s12931-022-02105-7>
162. Dimic-Janjic S, Hoda MA, Milenkovic B, et al. The usefulness of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio for diagnosis and assessment of COPD severity. *Eur J Med Res.* 2023;28(1):127. Available at: <https://doi.org/10.1186/s40001-023-01094-7>
163. Demedts IK, Morel-Montero A, Lebecque S, et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. *Thorax.* 2006;61(3):196. Available at: <https://doi.org/10.1136/thx.2005.042432>
164. Hodgin KS, Donovan EK, Kekes-Szabo S, et al. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (*Polygonum cuspidatum*), Luteolin, and Fisetin (*Rhus succedanea*). *Int J Environ Res Public Health.* 2021;18(5):2483. Available at: <https://doi.org/10.3390/ijerph18052483>
165. Rebello CJ, Beyl RA, Lertora JLL, et al. Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. *Diabetes Obes Metab.*

- 2020;22(1):91. Available at:
<https://doi.org/10.1111/dom.13868>
166. Moriwaki M, Kito K, Nakagawa R, et al. Mutagenic, Acute, and Subchronic Toxicity Studies of the Hesperetin-7-Glucoside- β -Cyclodextrin Inclusion Complex. *Int J Toxicol*. 2022;42(1):50. Available at:
<https://doi.org/10.1177/10915818221134022>
167. EFSA Panel on Dietetic Products, Nutrition (NDA), Allergies, et al. Statement on the safety of taxifolin-rich extract from Dahurian Larch (*Larix gmelinii*). *EFSA J*. 2017;15(11):e05059. Available at:
<https://doi.org/10.2903/j.efsa.2017.5059>
168. Zhang YY, Bai J, Xu MY, et al. Study on baicalin on liver and kidney toxicity in male rats. *Chin J Ind Hyg Occup Dis*. *Chin J Ind Hyg Occup Dis*. 2021;39(3):169. Available at:
<https://doi.org/10.3760/cma.j.cn121094-20200326-00158>
169. Barnett CF, Moreno-Ulloa A, Shiva S, et al. Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (-)-epicatechin in healthy volunteers. *Food Funct*. 2015;6(3):824. Available at:
<https://doi.org/10.1039/C4FO00596A>
170. Chen IJ, Liu CY, Chiu JP, et al. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. *Clin Nutr*. 2016;35(3):592. Available at:
<https://doi.org/10.1016/j.clnu.2015.05.003>
171. Fried MW, Navarro VJ, Afdhal N, et al. Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon Therapy. *JAMA*. 2012;308(3):274. Available at:
<https://doi.org/10.1001/jama.2012.8265>